Cefaseptin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefaseptin

Property Description
Active ingredient Cefalexin (Cephalexin)
Form Oral tablet or capsule
Pharmacological class beta-lactam antibiotic, first-generation cephalosporin
General purpose Treats susceptible bacterial infections
Origin Semi-synthetic (derived from a fungal source)

Cefaseptin is a proprietary medicine whose single active ingredient is Cefalexin (also spelled Cephalexin), which is used to treat infections caused by susceptible bacteria. It is chemically classified as a beta-lactam antibiotic belonging to the first-generation cephalosporin class. This classification is significant as it indicates a strong activity profile against certain common bacteria. Drugs in this class are widely used to fight common bacterial pathogens and are clinically recognized for their effectiveness against a wide spectrum of bacteria.

As a prescription-only (Rx) systemic anti-infective, Cefaseptin is intended to be absorbed into the body to target bacterial pathogens. Cefalexin is one of the oral agents within the first-generation cephalosporins, which are compounds derived initially from the fungus Acremonium chrysogenum.


Cefalexin: Composition, Form, and Differentiation

The active ingredient, Cefalexin (typically present as Cefalexin monohydrate), is a semi-synthetic compound delivered primarily in the form of an oral tablet or capsule. Cefaseptin is a single-entity medicine, meaning its effects are due solely to Cefalexin itself. This brand is often positioned for veterinary use, specifically for bacterial infections in companion animals like dogs and cats.

Cefalexin is considered acid-stable, which allows it to be effectively absorbed when administered via the oral route (by mouth). It is a stable semisynthetic cephalosporin antibiotic intended for oral administration. This stability ensures the medication remains effective when taken by mouth, offering an essential difference from injectables.


General Purpose: How Does Cefaseptin Help?

The primary therapeutic goal of Cefaseptin is to eliminate bacterial infections by actively killing the harmful microbes. It achieves this by acting as a bactericidal agent. The drug works by binding to and inactivating critical proteins required for the bacteria to build and maintain their cell wall structure.

By inhibiting the final step of cell wall synthesis, the medication causes the wall to break down, leading to the destruction of the bacterial cell. This targeted, destructive process provides a reliable means to help the body clear the infection and prevent bacteria from multiplying further. A typical, neutral use scenario is the treatment of a bacterial skin infection (pyoderma) in an animal.

Regulatory References

  1. NIH Cephalexin and First-Generation Cephalosporin Use
  2. NIH: Mechanism of Action

What side effects are possible with Cefaseptin?

Possible Side Effects and Safety Information

The safety profile for Cefaseptin, which contains the active ingredient Cefalexin, is established through official regulatory documents that organize adverse reactions by frequency and affected organ system. The most common adverse reactions documented are related to the gastrointestinal system, including diarrhea, nausea, vomiting, dyspepsia, and abdominal pain.


Systemic Safety Concerns and Serious Reactions

Adverse effects are also documented across other system-organ classes, including the skin, nervous system, and blood and lymphatic system. The regulatory label highlights the potential for serious adverse reactions, although these are rare. These include severe hypersensitivity events, such as anaphylaxis, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis. Additionally, Cefalexin, like other broad-spectrum antibiotics, is associated with the risk of Clostridium difficile-associated diarrhea (CDAD), which can occur during or up to two months after the end of treatment.


Specific Safety Constraints

The medicine's safety profile includes specific constraints based on known risks. Cefaseptin is contraindicated in individuals with a known hypersensitivity to Cefalexin or other drugs in the cephalosporin class. Patients with a history of penicillin allergy require careful review due to the potential for cross-hypersensitivity. The official labeling also notes that patients with renal impairment may require lower dosage, as the drug is primarily eliminated by the kidneys, and the risk of toxic reactions, such as seizures, is greater in this population. Furthermore, Cefalexin is known to be excreted in breast milk, which is a factor considered in official safety recommendations.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information defines the Cefaseptin (Cefalexin) overdose profile based on documented physical manifestations and required emergency actions.

Overdose manifestations primarily involve gastrointestinal distress, including nausea, vomiting, diarrhea, and epigastric discomfort. A specific documented finding is the presence of hematuria (blood in the urine).

Severe overdosage is associated with potential risks to the Central Nervous System (CNS) and the renal system. The regulatory profile documents the potential for neurotoxicity, which may manifest as seizures or encephalopathy. This risk is notably increased in individuals with impaired renal function, pre-existing CNS disorders, or in elderly patients.

In the event of any suspected overdose, regulatory labeling mandates seeking immediate medical attention. This involves contacting a Poison Control Center or emergency services without delay, even if symptoms are not immediately visible. Due to the fact that no specific antidote is known, management is limited to general symptomatic and supportive care combined with close clinical and laboratory monitoring, particularly of renal function.

Therapeutic Uses of Cefaseptin

Cefaseptin is commonly used in clinical settings involving symptoms related to inflammatory or irritative states due to susceptible bacterial infections. Its therapeutic scope is considered relevant across multiple domains, including infections of the skin and soft tissues, the urinary and respiratory tracts, bone infections, and otitis media (middle ear infections).


Symptom Management and Clinical Contexts

The medication is considered relevant for conditions presenting with acute episodes, helping to address symptom clusters that may become intense or disruptive. For instance, Cefaseptin supports the management of symptoms related to physical discomfort, such as the pain, swelling, and tenderness associated with bacterial skin conditions like cellulitis and abscesses. It assists in managing functional distress, such as the painful urination linked to Urinary Tract Infections (UTIs), and is also applied in addressing conditions marked by increased physiological stress, such as bone infections. Furthermore, it may be part of symptomatic management in contexts where short-term symptomatic assistance is needed for infection prophylaxis, such as prior to certain surgical or dental procedures.

“It is commonly used across domains where additional symptomatic support is needed, contributing to easing the overall symptom load.”


Quick Fact: Support for Symptoms related to inflammatory or irritative states Cefaseptin is commonly used to help with symptoms related to physical discomfort and inflammatory or irritative states. This may assist with maintaining functional stability during symptomatic periods.

Regulatory References

  1. NIH DailyMed official prescribing information

Eligibility and Restrictions for Use

Who Can and Cannot Use Cefaseptin?

Cefaseptin (Cefalexin) is subject to specific population eligibility rules defined by governmental regulatory authorities. The primary determinant of non-eligibility is a history of hypersensitivity.

Contraindicated Populations

Cefaseptin is absolutely contraindicated for patients with a documented allergy to the active ingredient, Cefalexin, or to any antibiotic belonging to the cephalosporin class of drugs.


Condition-Based and Age-Related Eligibility

Population Group Eligibility Status (Regulatory Basis)
General Adult and Pediatric Use Approved. Safety and efficacy are established for use in both adults and children.
Impaired Renal Function Conditional/Restricted. Requires careful selection of a reduced total daily dose, especially with marked impairment.
Penicillin Allergy History Restricted. Use is conditional due to the documented potential for cross-hypersensitivity.
Pregnancy (Category B) Conditional. Permitted only if clearly needed.
Lactation Conditional. The drug is excreted in human breast milk; use requires caution.
Infants (<1 month) Not Established. Safety and efficacy data are limited or not established for this specific age group.

What should I know about interactions with other medicines?

The official regulatory profile for Cefaseptin (Cefalexin) documents specific interaction patterns concerning exposure modification, additive pharmacodynamic risk, and administrative timing constraints.

Pharmacokinetic Interactions and Exposure Alteration

Probenecid is documented to inhibit the renal excretion of Cefalexin, a pharmacokinetic interaction that results in significantly increased Cefalexin serum concentrations. Conversely, Cefalexin itself is officially stated to increase the plasma exposure (AUC and Cmax) of Metformin by reducing its renal clearance.

Pharmacodynamic Risk and Restrictions

Co-administration with Anticoagulants (e.g., Warfarin) is associated with a risk of reduced prothrombin activity and prolonged prothrombin time. Similarly, use with Nephrotoxic Agents like Aminoglycoside antibiotics or Loop Diuretics may increase the risk of nephrotoxicity. The medicine is also documented to decrease the efficacy of Oestrogen-containing Oral Contraceptives.

Administrative Constraints

Zinc-containing products interfere with the absorption of Cefalexin and must be administered at least three hours after the Cefalexin dose. Additionally, Cefalexin may interfere with certain clinical testing, potentially causing a false-positive reaction for glucose in the urine with copper-reduction test methods.

Mechanism of Action

Covalent Inhibition of Bacterial Cell Wall Enzymes

The mechanism of Cefaseptin is centered on the rapid and irreversible inactivation of essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs), primarily the transpeptidases. These proteins are critical for the final stage of peptidoglycan cross-linking, a process essential for the structural integrity of the bacterial cell wall. By covalently binding to the PBP active site, the drug permanently disrupts the bacteria's ability to maintain its protective structure.

Mechanistic Cascade: Osmotic Lysis and Pathogen Destruction

The functional consequence of inhibiting the PBPs is the induction of osmotic instability. When the cell wall is no longer properly constructed, it cannot withstand the high internal pressure of the bacterial cell, leading to the rapid influx of water. This results in the rupture and death of the organism, a process termed lysis. This destructive action defines the bactericidal nature of the mechanism, which results in the systemic reduction of the bacterial pathogen population.

️ Limitations via Enzymatic Resistance

The drug's mechanism of action is constrained by biological counter-mechanisms developed by resistant bacteria. The most common limitation is the production of beta-lactamase enzymes, which actively cleave and inactivate the drug's beta-lactam ring, thereby preventing the covalent binding step to the PBPs. This target-site interference prevents the subsequent bactericidal process.

Dosage and Administration Information

Official Administration Protocol

Cefaseptin (Cefalexin) is administered exclusively via the oral route, available in forms such as capsules, tablets, and a powder for oral suspension. The medication is acid-stable and may be taken without regard to meals, providing flexibility in the dosing schedule.

The dosage and frequency are determined by the severity of the infection. The standard adult dosing is typically 250 mg every 6 hours or 500 mg every 12 hours, with doses spaced equally throughout the day. For more serious infections, the total daily amount may be increased up to a maximum of 4 grams, which must be administered in equally divided doses.


Course Duration and Adjustments

Procedural Requirement Official Guideline
Typical Course Duration Generally 7 to 14 days, though a minimum of 10 days is required for beta-hemolytic streptococcal infections.
Renal Impairment Dose adjustment is mandatory for severe renal impairment (creatinine clearance <30 mL/min), with specific lower maximum daily doses established for these cases.
Suspension Use The powder form must be reconstituted with a specific volume of water and shaken well to ensure the medication is properly dispersed before administration.

The following details outline the sequence and conditions for administering the medicine.

Recent Clinical Evidence

Cefaseptin: Recent Clinical Evidence

Cefaseptin (active ingredient: Cefalexin) was studied for use in infections caused by susceptible bacteria. The research base includes various types of trials, such as Randomized Controlled Trials (RCTs), which explored Cefalexin in comparison to other treatments, and Systematic Reviews that gather and evaluate data from multiple studies. These studies primarily aim to explore patterns related to how infections were observed in research and what factors are associated with those patterns.


Evidence from Studies for Skin and Soft Tissue Infections

The research for conditions like cellulitis and impetigo primarily relied on short-term RCTs. Researchers monitored outcomes such as the Clinical Cure Rate, which tracked measurements of the physical signs monitored in the study, and Treatment Failure. Findings describe patterns observed in the studies regarding the proportion of observed patients whose conditions met the definition of clinical success during defined time intervals.

The research so far suggests a focus on acute, short-term treatment effects. However, the evidence is limited regarding the optimal dose regimen for certain types of skin infections, which remains uncertain and is the focus of ongoing research. Furthermore, long-term effects are not fully established, meaning there is limited information for long-term outcomes such as the risk of the condition returning after the study period ends.


Evidence in Special Patient Populations and Gaps

Research explored the use of Cefalexin across different patient groups, with attention paid to children and infants. Specific Pharmacokinetic/Pharmacodynamic (PK/PD) studies research examined these populations because their bodies process medicines differently than adults. These studies help researchers evaluate potential dose schedules in the youngest patients.

Certainty remains low when comparing Cefalexin against some of the newer generation antibiotics, as comparative evidence is lacking from recent, large-scale RCTs. Additionally, the results apply only to the populations studied, and dedicated clinical evidence for specific comorbid conditions or during pregnancy is limited.

Key Studies & References CEPHALEXIN capsule prescribing information (Official Drug Label)

Frequently Asked Questions (FAQ)

Common questions about Cefaseptin (FAQ)


Q: Is Cefaseptin the same as other similar-sounding drugs?

A: Cefaseptin is a specific brand name for the active ingredient Cefalexin (also spelled Cephalexin). While it belongs to a family of medicines called cephalosporins, these drugs have different active ingredients and are not identical. Official information indicates that Cefalexin is also available under other brand names, such as Keflex, and as generic versions.

Q: How quickly does Cefaseptin start working after the first use?

A: The drug is described in official pharmacokinetic research as rapidly absorbed after it is taken by mouth. Peak concentrations of the medicine in the blood are generally reached within one to two hours after a dose. This rapid absorption describes how the medicine becomes available to begin its mechanism of action against susceptible bacteria.

Q: Is it okay to use Cefaseptin if I am already taking supplements?

A: Regulatory information indicates that Cefaseptin should not be taken at the same time as zinc supplements or products containing zinc. This is because zinc may reduce the body's absorption of the medicine. Official guidance recommends separating the use of Cefaseptin and zinc-containing products by at least three hours.

Q: Can Cefaseptin cause tiredness or dizziness?

A: Official safety documents list dizziness and fatigue (tiredness) as documented adverse reactions associated with Cefalexin use. These effects are generally noted as non-frequent. Regulatory sources document a range of possible effects.

Q: What are the signs of a serious reaction to Cefaseptin that I should know about?

A: Official safety profiles document that, although rare, severe adverse reactions may occur, including extreme allergic responses like anaphylaxis and serious skin conditions. Official warnings note that symptoms of serious reactions may include sudden swelling of the face or tongue, or difficulty breathing.

Q: Can Cefaseptin be used by children?

A: Yes, Cefaseptin is approved for use in the pediatric population (children). However, safety and effectiveness data are not established in official documents for infants less than one month old. Professional guidance is required to determine appropriate use in any child.

Q: Is Cefaseptin safe to use during pregnancy?

A: Official regulatory documents place Cefalexin in Pregnancy Category B. Its use is conditional, meaning official information states it is permitted only if clearly needed after professional evaluation.

Q: What information is available about Cefaseptin use while breastfeeding?

A: Regulatory documents confirm that Cefalexin is excreted in human breast milk. Use during lactation is described as conditional. Official guidance documents that the drug is excreted in human breast milk and requires professional evaluation.

Q: Does Cefaseptin have any effect on birth control pills?

A: Yes, official regulatory documents state that Cefalexin is known to decrease the efficacy (effectiveness) of oestrogen-containing oral contraceptives (birth control pills). This interaction is a documented risk for patients using this type of contraception.

Q: What happens if Cefaseptin is used for a longer period than described?

A: Official safety warnings state that prolonged use of Cefalexin may lead to the overgrowth of non-susceptible organisms, including different types of bacteria and fungi. Treatment duration is determined by the specific condition being addressed.

Q: Can Cefaseptin affect laboratory test results?

A: Yes, official information indicates that Cefalexin may interfere with certain clinical tests. Specifically, it can potentially cause a false-positive reaction for glucose in the urine when using copper-reduction test methods.

Q: What are the known drug-drug interactions listed in the regulatory documents?

A: Official documents describe known interactions where Cefalexin can affect the levels of other drugs, such as Probenecid and Metformin. It is also associated with an increased risk when used alongside Anticoagulants (e.g., Warfarin) and Nephrotoxic Agents (drugs that can harm the kidneys).

Q: Why is Cefaseptin sometimes described as a 'broad-spectrum' drug?

A: Cefalexin is documented in official sources as a broad-spectrum cephalosporin antibiotic because it shows bactericidal activity (it actively kills bacteria) against a wide range of both Gram-positive and Gram-negative bacteria. This wide activity range gives it the classification of 'broad-spectrum'.

Q: What should I do if I forget to use Cefaseptin?

A: Patient guidelines from official sources describe that a missed dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Regulatory guidance describes that two doses should never be taken together to compensate for a missed dose.

Q: Are there any common food or drink items that interact with Cefaseptin?

A: Official labeling states Cefalexin is stable and may be taken without regard to meals, indicating that general food items do not significantly interfere with its absorption or effectiveness. Apart from the required separation from zinc-containing products, no other common foods or drinks are specifically documented as interacting.

Q: Is a mild upset stomach a common experience with Cefaseptin?

A: Yes, official safety data indicates that the most frequent adverse reactions are related to the gastrointestinal system. These effects, which can be described as an upset stomach, include diarrhea, nausea, vomiting, dyspepsia (indigestion), and abdominal pain.

Q: Is there a risk of developing resistance when using Cefaseptin?

A: Regulatory guidance emphasizes that the medicine should be used only for infections proven or strongly suspected to be caused by bacteria. Regulatory documents state that using the medicine only when needed helps reduce the potential development of drug-resistant bacteria.

Q: Can Cefaseptin be used for skin infections?

A: Yes, the official regulatory documents list Cefalexin as indicated for the treatment of skin and skin structure infections when those infections are caused by susceptible microorganisms. This is one of the primary uses documented across several international regulatory bodies.

Q: Is Cefaseptin known to interact with alcohol?

A: The official product labeling for Cefalexin does not explicitly list alcohol as a drug-drug interaction. However, alcohol consumption may enhance common side effects such as dizziness and nausea. Professional guidance should be sought regarding alcohol use with this and other antibiotics.

Q: Is Cefaseptin typically available over-the-counter or only by prescription?

A: Cefaseptin, containing Cefalexin, is consistently defined across government sources as a prescription-only (Rx) systemic anti-infective medicine. This means it is available only with a prescription from a qualified healthcare professional.

Q: Is it true that Cefaseptin should be spaced out from other medications?

A: Official product information requires Cefalexin to be spaced at least three hours apart from zinc-containing products to avoid interference with absorption. Other medications do not have a general requirement to be spaced out unless specifically noted in the full interactions list.

Q: How long does Cefaseptin typically stay in the body after the last use?

A: In individuals who have normal kidney function, official pharmacokinetic studies show that the plasma half-life of Cefalexin is approximately one hour. This means the medicine is typically eliminated from the body within several hours after the last dose.

Q: Is Cefaseptin a drug that is used for preventing infections?

A: Regulatory documents primarily indicate Cefalexin for the treatment of infections caused by susceptible bacteria. However, it is also documented for use in some procedures where preventing bacterial endocarditis may be necessary.

Q: Are there different versions or brands of Cefaseptin?

A: Yes, Cefaseptin is a brand name for the generic drug Cefalexin. The generic version (Cefalexin) is widely available under other brand names and as generic options, as noted in official drug lists.

Q: Can Cefaseptin cause changes in mood or behavior?

A: Official safety data lists adverse reactions in the nervous system category, including non-frequent reports of agitation and confusion. Rare reports of serious neurotoxicity, such as encephalopathy (a brain condition), have also been documented, primarily in patients with impaired kidney function.

Q: Do other countries use Cefaseptin for the same conditions?

A: Regulatory documents published by different international bodies, such as the EMA in Europe and the FDA in the US, list Cefalexin for treating similar types of infections. These commonly include respiratory tract, skin and soft tissue, and genito-urinary tract infections caused by susceptible bacteria.

Q: What if I have diabetes—can I use Cefaseptin?

A: Patients with diabetes require special consideration. Official documents note that Cefalexin interacts with Metformin, which may increase the level of Metformin in the body. Additionally, some liquid formulations of the medicine contain excipients like sucrose (sugar), which must be accounted for in patient evaluation.

Q: Does Cefaseptin's effectiveness change if it's taken with food?

A: No. The official product labeling states that Cefalexin is acid stable and may be given without regard to meals. Clinical data indicates that taking it with food is largely a matter of patient comfort and does not significantly affect its overall therapeutic effectiveness.

Q: Are there any long-term health concerns associated with Cefaseptin use?

A: Official warnings state that prolonged use of this antibiotic may lead to the overgrowth of non-susceptible organisms. Furthermore, while core research evidence is available for short-term effects, it officially notes that long-term effects are not fully established.

How should Cefaseptin be stored and disposed of?

The official regulatory instructions for storing and disposing of Cefaseptin (Cephalexin) focus on maintaining the product's stability and ensuring environmental safety.

Official Storage Conditions

Cefaseptin tablets and capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed and stored away from excess heat and moisture.

Reconstituted Suspension Stability

If the medicine is the oral suspension form and has been reconstituted with water, it requires refrigeration at 2 C to 8 C (36 F to 46 F). The suspension is stable for only 14 days under these conditions, and any remaining portion must be discarded afterward.

Child Safety and Disposal

All forms of Cefaseptin must be kept out of the reach of children. Unused or expired medication must be disposed of according to local requirements, typically via a community drug take-back program. Official instructions state not to flush the product down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefaseptin found in:

A-Z Index: